NEW YORK (GenomeWeb) – Precipio said it has inked a deal with Italy's Euroclone Diagnostica to sell Precipio's Ice Cold-PCR DNA enrichment products for use with liquid biopsies.
The distribution deal is exclusive in Italy and non-exclusive in the rest of Europe, Precipio said.
Ice Cold-PCR (ICP) preferentially enriches mutant DNA sequences over wild-type DNA through selective amplification, enabling it to detect tumor DNA in blood samples at levels as low as 0.1 percent. This enables blood-based somatic mutation testing, more accurate diagnoses, and continual monitoring of patients undergoing cancer therapy, Precipio said.
Milan-based Euroclone sells industrial and research products for cytogenetics, cell biology, and contamination control from global scientific brands, a number of which are used in conjunction with Precipio's products including Biofire Diagnostics' high-resolution melt, Roche's RT-PCR, and New England Biolabs reagents and enzymes for next-generation sequencing.
"Our collective analysis indicates significant potential demand for the improved monitoring and cancer care ICP provides," Precipio Chief Commercial Officer Stephen Miller said in a statement. "The plan is for Italy to serve as a staging area for rapid expansion into other EMEA markets such as the UK, France, Germany, Spain, and Scandinavia."